Fig. 1 · Structure

Documents & Downloads

Oleuropein

Cat. No. A12095 CAS 32619-42-4
Oleuropein is a phenylethanoid, a type of phenolic compound found in olive leaf from the olive tree together with other closely related compounds such as 10-hydroxyoleuropein, ligstroside, and 10-hydroxyligstroside.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PPARγ  
Apoptosis  
Aromatase  

Cellular Effect

Cell Line Activity Value Description Reference
B16-F1 IC50 283.9 μM Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay [PMID: 28551177]
HCT-116 IC50 181.86 μM Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay [PMID: 28551177]
HeLa IC50 265.28 μM Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay [PMID: 28551177]
HL-60 IC50 54.26 μM Antiproliferative activity against human HL60 cells after 72 hrs by MTT reduction assay [PMID: 28551177]
K562 IC50 64.73 μM Antiproliferative activity against human K562 cells after 72 hrs by MTT reduction assay [PMID: 28551177]
MCF7 IC50 161.57 μM Antiproliferative activity against human MCF7 cells after 72 hrs by MTT reduction assay [PMID: 28551177]
RAW264.7 IC50 > 80 μM Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent-based assay [PMID: 32936639]
SK-BR-3 IC50 160.44 μM Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay [PMID: 28551177]

Oleuropein Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Oleuropein from 3 published references. In vitro models include MIA PaCa-2 cells.

Oleuropein In Vitro Studies

Oleuropein was evaluated in MIA PaCa-2 cells using a CCK8 viability assay. Treatment inhibited proliferation dose dependently, with an IC50 of 150.1 µM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibited the proliferation of MIA PaCa-2 cells

Cell-based study · MIA PaCa-2 cells [1]

MIA PaCa-2 cells were treated with Oleuropein and assessed using a CCK8 viability assay. Oleuropein inhibited proliferation dose dependently, with an IC50 of 150.1 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK8 viability assayIC50 150.1 µM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–300 μM
Exposure duration
72 h
Vehicle
0.5% DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Oleuropein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Treatment with Olive Biophenols Reduces Pancreatic Cancer Cell Viability (S1, S3); 4. Materials and Methods > 4.3. Assessment of Cell Growth Inhibition (S70, S71)

CCK8 viability assay: CCK8 viability assay; comparator: 0.5% DMSO (vehicle control) — 2. Results > 2.1. Treatment with Olive Biophenols Reduces Pancreatic Cancer Cell Viability (S1, S3)

Oleuropein In Vivo Studies

In WD-fed mice undergoing myocardial IRI surgery, Oleuropein pretreatment significantly reduced infarct size compared to the respective vehicle group. In HFD-fed male mice receiving Oleuropein, food intake was 17.0 ± 0.1 g/week, with HFD as the control. In WD-fed mice, Oleuropein significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group. [2,3]

Reduced infarct size in WD-fed mice

Animal study · C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7) [2]

In WD-fed mice undergoing myocardial IRI surgery, Oleuropein pretreatment at 20.6 mg/kg by oral gavage significantly reduced infarct size compared to the respective vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infarct sizeReported result Pretreatment with isolated OL, OC and OA significantly reduced the infarct size compared to the respective vehicle group.[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
for the last 6 weeks daily
Vehicle
sterile normal saline (NaCl 0.9 %)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oleuropein 20.6 mg/kgVehicle NS (n = 6)Pretreatment with isolated OL, OC and OA significantly reduced the infarct size compared to the respective vehicle group.[2]
Oleuropein 20.6 mg/kg
Model: C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7)
Methods and source locations

Compound reported in the paper: Oleuropein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Compounds isolation, purification and identification (S17); Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S40, S41, S42, S43, S50); Materials and methods > Infarct size measurement after IRI (S91, S93, S94); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192); Fi...

infarct size: infarct size; comparator: Vehicle NS (n = 6) — Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S50); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192)

Oleuropein 20.6 mg/kg · Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S41, S43); Results > Chronic pretreatment with OL, OC and OA at nutritional dose reduces myocardial infarct size in healthy and MS-burdened mice (S192)

Food intake in HFD-fed mice

Animal study · Five-week-old male C57BL/6JOlaHsd mice; HFD-OLE, n = 4 [3]

HFD-fed male mice received Oleuropein at 20 mg/kg by daily oral gavage for 5 weeks, with HFD as the control. Food intake in the treated group was 17.0 ± 0.1 g/week.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Food intake (g/week)Food intake 17.0 ± 0.1 g/week[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily; for 5 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oleuropein 20 mg/kgHFD17.0 ± 0.1 g/week[3]
Oleuropein 20 mg/kg
Model: Five-week-old male C57BL/6JOlaHsd mice; HFD-OLE, n = 4
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Oleuropein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and Study Design (S8, S12); Table 1 legend (S90); Table 1 (T1.h1, T1.r1)

Food intake (g/week): Food intake (g/week); comparator: HFD — Table 1 (T1.h1, T1.r1)

Oleuropein 20 mg/kg · Materials and Methods > Animals and Study Design (S12); Table 1 (T1.h1, T1.r1)

Decreased fasting glucose in WD-fed mice

Animal study · C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7) [2]

WD-fed mice received Oleuropein at 20.6 mg/kg by daily oral gavage during the last 6 weeks. Treatment significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
fasting glucose levels at 14 weeksReported result Treatment with OL resulted in significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
for the last 6 weeks daily
Vehicle
sterile normal saline (NaCl 0.9 %)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oleuropein 20.6 mg/kgVehicle NS (n = 6)Treatment with OL resulted in significantly decreased fasting glucose levels at 14 weeks compared to the Vehicle (NS) group[2]
Oleuropein 20.6 mg/kg
Model: C57Bl6 mice were fed with WD for 14 weeks to induce MS; OL 20.6 mg/kg (n = 7)
Methods and source locations

Compound reported in the paper: Oleuropein

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Compounds isolation, purification and identification (S17); Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S40, S41, S42, S43); Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195); Fig. 2 legend (S285)

fasting glucose levels at 14 weeks: fasting glucose levels at 14 weeks; comparator: Vehicle NS (n = 6) — Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195)

Oleuropein 20.6 mg/kg · Materials and methods > In vivo experimental protocols > 2ndseries of experiments: Investigation of OL, HT, OC and OA effects on myocardial IRI in the presence of MS (S41, S43); Results > OL mitigated hyperglycemia and increased insulin levels in plasma (S195)

Specifications

Manufacturer Adooq Bioscience
CAS Number 32619-42-4
Formula C25H32O13
Molecular Weight 540.1
SMILES
C/C=C/1\[C@@H](C(=CO[C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)OC)CC(=O)OCCC3=CC(=C(C=C3)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 95 mg/mL (175.76 mM)
Water Warmed: 95 mg/mL (175.76 mM)
Ethanol Warmed: 95 mg/mL (175.76 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
PBS

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Oleuropein Research References

  1. [1] Goldsmith CD, Bond DR, Jankowski H, et al. The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells. Int J Mol Sci (2018). PMID: 30004416 DOI: 10.3390/ijms19071937 Source material
  2. [2] Christodoulou A, Nikolaou PE, Symeonidi L, et al. Cardioprotective potential of oleuropein, hydroxytyrosol, oleocanthal and their combination: Unravelling complementary effects on acute myocardial infarction and metabolic syndrome. Redox Biol (2024). PMID: 39153251 DOI: 10.1016/j.redox.2024.103311 Source material
  3. [3] Lombardo GE, Lepore SM, Morittu VM, et al. Effects of Oleacein on High-Fat Diet-Dependent Steatosis, Weight Gain, and Insulin Resistance in Mice. Front Endocrinol (Lausanne) (2018). PMID: 29615982 DOI: 10.3389/fendo.2018.00116 Source material

Added to your cart

View Cart Checkout
Loading...